“…High harpagoside doses administered to rats showed no clinical or pathological reactions (Whitehouse et al, 1983). However, its use is contraindicated in instances of gastric or duodenal ulcers, where the bitter compounds can stimulate stomach acid secretion (Hedberg, 1987;McGuffin et al, 1997;Blumenthal et al, 1998;Brinker, 1998); in patients with gallstones, due to its tendency to increase bile production in the liver (Brinker, 1998); in patients that use the blood thinning drug Warfarin because it may increase its effects and cause skin bruising (Ebadi, 2002); and in diabetics where an excessive dose may interfere with blood pressure and cardiac therapy (Newell et al, 1996).…”